February 7, 2014
The Second Wave Arrives
Two more HCV drugs were newly approved in late 2013: the protease inhibitor simeprevir (Olysio) and the nucleotide polymerase inhibitor sofosbuvir (Sovaldi).
By comparison to the two previously approved HCV protease inhibitors, simeprevir appears to be significantly more friendly toward coadministration with HIV medications (particularly HIV protease inhibitors) and has a high efficacy rate in HCV treatment-naive coinfected patients, even allowing many to dramatically shorten the typical course of HCV therapy. However, the drug must still be coadministered with peginterferon, leaving toxicity as a major issue.
Peginterferon is also part of a sofosbuvir-containing regimen at the moment, but only for genotype 1 patients. For patients with genotype 2 or 3, the drug is dosed alongside only ribavirin, and dramatically lower adverse event rates accompany that indication. Sofosbuvir also appears to have virtually no interactions with HIV antiretrovirals.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|HIV-Positive Individuals on Treatment Lose More Years of Life to Smoking Than to HIV|
|More Age-Related Illnesses in Older People With HIV Than Comparable HIV-Negatives|
|Novel, Broadly Active HIV Inhibitor Shows Potential for Vaccine|
|This Week in HIV Research: Another Route for Gene Therapy; Drugmaker and University Team Up for HIV Cure|
|Advocates for Women Talk About CROI 2015|
|This Week in HIV Research: HIV Reservoirs Remain Obstacles to Cure; "Redesigned" Antibodies Show Promise; and Is 85% Adherence Enough?|